Floatz logo

Immunocytokine Nhs-Il12

Metastatic HER2 Negative Breast Adenocarcinoma

M.D. Anderson Cancer Centerprotein_peptidePhase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Metastatic HER2 Negative Breast Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BB
Inno-206
Virginia Commonwealth University
Phase 3BB
TRASTUZUMAB
Academic and Community Cancer Research United
Phase 3BB
Carboplatin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Immunocytokine Nhs-Il12 is also rated in:

small intestine cancerDormant
CC
Indicative ·
44 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
44 / 100
View asset →
HPV CancersDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →